[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C@@H1][C][/C][=Branch2][=Branch1][S][=C][/C][C@@H1][C][C@@H1][Branch2][Ring2][Ring1][C][C@@][Branch1][Ring2][O][Ring1][=Branch1][C][/C][=Branch1][Ring2][=N][\\O][C][/C@@H1][Branch1][P][C@H1][Branch1][Ring2][O][Ring1][#Branch2][/C][=Branch1][#Branch1][=C][/C][Branch1][C][C][C][/C][C][O][C][=Branch1][C][=O][C@@H1][C][=C][Branch2][Ring1][#Branch2][C@H1][Branch2][Ring1][Branch1][C@@H1][C@][Ring1][=Branch1][Branch1][=C][/C][=Branch1][#Branch1][=C][/C][=C][\\-Ring2][Ring2][#Branch1][/C][O][Ring1][Branch2][O][O][C][/C]"}, {"from": "gpt", "value": "The molecule is a potent, broad-spectrum endectocide (antiparasitic that is active against endo- and ecto-parasites) with activity against nematodes, insects, and acari. It was first used in cattle followed by an approved use in general animals. It is a semi-synthetic methoxine derivative of nemadectin which is a 16-member pentacyclic lactone of the milbemycin class. Moxidectin differs by the absence of a disaccharide moiety on carbon 13, a substituted olefinic side chain at carbon 25 and a unique methoxime moiety at carbon 23. Due to these modifications, moxidectin is classified as a second generation macrocyclic lactone. Moxidectin was developed by Medicines Development for Global Health and FDA approved in June 13, 2018."}]